This filing details a Power of Attorney granted by John Bencich, Chief Financial Officer of AEON Biopharma, Inc., to Alexander B. Wilson and Jennifer Sy. The attorneys-in-fact are authorized to execute and file Section 13 and Section 16 reports (Schedules 13D/13G, Forms 3, 4, and 5) with the SEC and other authorities o...

This filing details the ownership of CASI Pharmaceuticals, Inc. by Alexander Zukiwski, the Global Chief Medical Officer. The filing, dated March 18, 2026, reports Zukiwski's direct ownership of various stock options. These options, all fully vested and exercisable, have an exercise price of $1.93 and an expiration date...

This SEC Form 3 filing discloses the initial beneficial ownership of stock options by Chunhua Wang, Chief Operating Officer of CASI Pharmaceuticals, Inc. The filing reports Wang's holdings of 14 stock option grants with varying expiration dates from 2028 to 2034. The options cover a total of 200,000 ordinary shares wit...

This filing is an Exhibit 24, a Power of Attorney document, for Michael MacLean, who is a director at Camp4 Therapeutics Corp. The document designates Josh Mandel-Brehm, Kelly Gold, and Thomas Danielski as attorneys-in-fact. They are authorized to execute and file Forms 3, 4, and 5 on behalf of Michael MacLean, in acco...

This SEC Form 3 filing discloses the initial beneficial ownership of Ardelyx, Inc. securities by Rajani Dinavahi, the company's Chief Medical Officer. The filing includes a power of attorney document executed on March 16, 2026, granting authority to company executives to file various SEC forms on Dinavahi's behalf. Din...